TITLE

Bromodomain 4 protein is a predictor of survival for urothelial carcinoma of bladder

AUTHOR(S)
Yang Yan; Feng-Qiang Yang; Hai-Min Zhang; Jun Li; Wei Li; Guang-Chun Wang; Jian-Ping Che; Jun-Hua Zheng; Min Liu
PUB. DATE
July 2014
SOURCE
International Journal of Clinical & Experimental Pathology;2014, Vol. 7 Issue 7, p4231
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
97436042

 

Related Articles

  • Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Schneider, Steven A; Sukov, William R; Frank, Igor; Boorjian, Stephen A; Costello, Brian A; Tarrell, Robert F; Thapa, Prabin; Houston Thompson, R; Tollefson, Matthew K; Jeffrey Karnes, R; Cheville, John C // Modern Pathology;May2014, Vol. 27 Issue 5, p758 

    No abstract available.

  • Technique, role of extended lymphadenectomy in bladder Ca. Katz, Mark H.; Steinberg, Gary D. // Urology Times;Oct2007, Vol. 35 Issue 12, p24 

    The article discusses on the significance of extended lymphadenectomy in the treatment of bladder cancer. Lymphadenectomy has been regarded as the conventional method for surgical management of advanced metastatic bladder cancer. Likewise, lymphadenectomy offers vital staging and prognostic...

  • Overexpression of fatty acid synthase in human urinary bladder cancer and combined expression of the synthase and Ki-67 as a predictor of prognosis of cancer patients. Sugino, Takashi; Baba, Keiichi; Hoshi, Nobuo; Aikawa, Ken; Yamaguchi, Osamu; Suzuki, Toshimitsu // Medical Molecular Morphology;Sep2011, Vol. 44 Issue 3, p146 

    To investigate the status of fatty acid synthase (FAS) in bladder tumors and evaluate its prognostic significance, we immunohistochemically examined the expression of FAS in normal urothelium, carcinoma in situ (CIS), and urothelial carcinoma (UC) in cystectomized bladder. In normal urothelium,...

  • Survival from bladder cancer in England and Wales up to 2001. Whelan, P. // British Journal of Cancer;9/2/2008 Supplement, Vol. 99, pS90 

    The article presents clinical commentary addressing the study on survival from bladder cancer up to 2001 in England and Wales. It outlines the analysis on urothelial cancers including transitional cell carcinoma (TCC) and urothelial cell carcinoma (UCC) which account for up to 90% of malignant...

  • Tumor abnormal protein (TAP) examination contributes to primary diagnosis of bladder cancer. Liqing Zhang; Xiuxia Guo; Yongzheng Min; Jianjiang Xu // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 10, p18528 

    Objective: This study aims to investigate the application value of tumor abnormal protein (TAP) examination in the diagnosis of urothelial carcinoma of the bladder. Method: Abnormal sugar chain glycoproteins in the peripheral blood of 87 patients with urothelial carcinoma of the bladder were...

  • Multi-Institutional Validation of the Predictive Value of Ki-67 Labeling Index in Patients With Urinary Bladder Cancer. Margulis, Vitaly; Lotan, Yair; Karakiewicz, Pierre I.; Fradet, Yves; Ashfaq, Raheela; Capitanio, Umberto; Montorsi, Francesco; Bastian, Patrick J.; Nielsen, Matthew E.; Muller, Stefan C.; Rigaud, Jérôme; Heukamp, Lukas C.; Netto, George; Lerner, Seth P.; Sagalowsky, Arthur I.; Shariat, Shahrokh F. // JNCI: Journal of the National Cancer Institute;1/21/2009, Vol. 101 Issue 2, p114 

    Several small single-center studies have reported a prognostic role for Ki-67 labeling index in advanced urothelial carcinoma of the urinary bladder. To investigate whether Ki-67 was a useful biomarker of oncological outcome after radical cystectomy for urothelial carcinoma, we assessed its...

  • Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience. Eiji Kikuchi; Jun Miyazaki; Kazuyuki Yuge; Masayuki Hagiwara; Daishi Ichioka; Takamitsu Inoue; Susumu Kageyama; Mikio Sugimoto; Koji Mitsuzuka; Yoshiyuki Matsui; Shingo Yamamoto; Hidefumi Kinoshita; Hironobu Wakeda; Kazuya Hanai; Hiroyuki Nishiyama // Japanese Journal of Clinical Oncology;Feb2016, Vol. 46 Issue 2, p163 

    Objective: There has been no clear evidence supporting similar chemo-responses for upper and lower urothelial carcinomas. Methods: We conducted a multicenter retrospective cohort study to analyze urothelial carcinoma patients who underwent systemic chemotherapy at 17 centers from 2004 to 2010. A...

  • Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer. Poyet, Cédric; Buser, Lorenz; Roudnicky, Filip; Detmar, Michael; Hermanns, Thomas; Mannhard, Doris; Höhn, Andrej; Rüschoff, Jan; Qing Zhong; Sulser, Tullio; Moch, Holger; Wild, Peter J. // Journal of Clinical Pathology;Oct2015, Vol. 68 Issue 10, p819 

    Objectives To evaluate the protein expression of connexin 43 (Cx43) in primary urothelial bladder cancer and test its association with the histopathological characteristics and clinical outcome. Methods A tissue microarray containing 348 tissue samples from 174 patients with primary urothelial...

  • Comprehensive Management of Upper Tract Urothelial Carcinoma. Koukourakis, Georgios; Zacharias, Georgios; Koukourakis, Michael; Pistevou-Gobaki, Kiriaki; Papaloukas, Christos; Kostakopoulos, Athanasios; Kouloulias, Vassilios // Advances in Urology;2009, Special section p1 

    Urothelial carcinoma of the upper urinary tract represents only 5% of all urothelial cancers. The 5-year cancer-specific survival in the United States is roughly 75% with grade and stage being the most powerful predictors of survival. Nephroureterectomy with excision of the ipsilateral ureteral...

  • CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma. Xue, Yijun; Wu, Gengqing; Wang, Xiaoning; Zou, Xiaofeng; Zhang, Guoxi; Xiao, Rihai; Yuan, Yuanhu; Long, Dazhi; Yang, Jun; Wu, Yuting; Xu, Hui; Liu, Folin; Liu, Min // Medical Oncology;Mar2013, Vol. 30 Issue 1, p1 

    Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently identified human oncoprotein that stabilizes the c-MYC protein. Herein, we aimed to investigate its expression pattern, clinical significance, and biological function in urothelial cell carcinoma (UCC) of the bladder. CIP2A...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics